Oncology patient preferences in reporting on symptoms

Simple item page
dc.contributor.authorAlyssa, L. Peechatkaen_US
dc.contributor.authorMillie, Gerzonen_US
dc.contributor.authorJenny, J. Lyen_US
dc.contributor.authorDallabrida, Susan M.en_US
dc.date.accessioned2020-05-06T08:34:23Z
dc.date.available2020-05-06T08:34:23Z
dc.date.issued2020-01
dc.description.abstractBackground:Collecting patient reported outcomes (PROs) in oncology clinical trials is becoming increasingly important. However, there is limited consensus on the most appropriatefrequency of PRO administration in oncology trials. The aim of this preliminary study is to examine the perspective of participants with a cancer diagnosis on the importance of completing PROs and to identify at what frequency participants prefer to report on their cancer-related symptoms.Methods:166 participants with a self-reported cancer diagnosis completed a multiple-choice online survey regarding perceptions of symptom importance and reporting preferences.Results:When asked about the benefit of reporting oncology-related symptoms daily, 44% of participants indicated there would be “very much” a benefit, 29% indicated there would be “quite a bit” of benefit, and 17% indicated there would be “somewhat” of a benefit. When asked about how frequently they would prefer to report symptoms, 41% of participants preferred “as they occur,” 36% preferred “once a day,” 18% preferred “once a week,” 4% preferred “twice a day,” and 1% preferred “every 4 hours”. Conclusions: PROs in oncology clinical research are most often collected at weekly, monthly, or longer intervals; however, meaningful fluctuations in cancer-related symptoms can occur more frequently. While concerns regarding patient burden are often raised to support infrequent reporting, these data suggest that participants would like to report symptoms with greater frequency, as episodic and daily reporting options were most popular. Based on these data, more frequent PRO data capture is not only feasible but perceived as important by individuals with canceren_US
dc.identifier.affiliationseResearch Technology (ERT), 500 Rutherford Ave, Boston MA, USAen_US
dc.identifier.citationAlyssa L. Peechatka, Millie Gerzon, Jenny J. Ly, Dallabrida Susan M.. Oncology patient preferences in reporting on symptoms. International Journal of Clinical Trials. 2020 Jan; 7(1): 11-17en_US
dc.identifier.issn2349-3240
dc.identifier.issn2349-3259
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200958
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3259.ijct20200201en_US
dc.subjectPatient reported outcomesen_US
dc.subjectOncologyen_US
dc.subjectFrequencyen_US
dc.subjectSymptomsen_US
dc.titleOncology patient preferences in reporting on symptomsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijct2020v7n1p11.pdf
Size:
249.99 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Clinical Trials